NASDAQ:CLNN

Clene (CLNN) Stock Price, News & Analysis

Clene logo
$3.66 -0.26 (-6.63%)
Closing price 11/16/2026 04:00 PM Eastern
Extended Trading
$3.76 +0.10 (+2.73%)
As of 11/16/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Clene Stock (NASDAQ:CLNN)

Advanced

Key Stats

Today's Range
$3.51
▼
$3.98
50-Day Range
$3.10
▼
$4.54
52-Week Range
$3.02
▼
$10.84
Volume
123,344 shs
Average Volume
98,640 shs
Market Capitalization
$52.70 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$34.00
Consensus Rating
Moderate Buy

Company Overview

Clene Inc. is a clinical-stage biopharmaceutical company developing nanotherapeutic treatments for neurodegenerative diseases. Founded in 2013 and based in Salt Lake City, Utah, the company focuses on research and development rather than marketed medicines.

Its lead investigational candidate, CNM-Au8, is a suspension of gold nanocrystals designed to support cellular energy production and protect nerve cells. Clene has studied CNM-Au8 in clinical programs for conditions including amyotrophic lateral sclerosis (ALS) and multiple sclerosis.

CNM-Au8 remains investigational and has not been established as an approved treatment. Clene’s work centers on evaluating its safety and potential benefits in neurological disease.

AI Generated. May Contain Errors.

Clene Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
52nd Percentile Overall Score

CLNN MarketRank™: 
2.586895725125 of 5 stars

Clene scored higher than 52% of companies evaluated by MarketBeat, and ranked 573rd out of 877 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Clene has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on no strong buy ratings, 6 buy ratings, no hold ratings, and 1 sell rating.

  • Upside Potential

    Clene has a consensus price target of $34.00, representing about 829.0% upside from its current price of $3.66.

  • Amount of Analyst Coverage

    Clene has only been the subject of 2 research reports in the past 90 days.

  • Read more about Clene's stock forecast and price target.
  • Earnings Growth

    Earnings for Clene are expected to decrease in the coming year, from ($1.05) to ($1.17) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Clene is -1.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Clene is -1.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Percentage of Shares Shorted

    4.04% of the float of Clene has been sold short.
  • Short Interest Ratio / Days to Cover

    Clene has a short interest ratio ("days to cover") of 5.06.
  • Change versus previous month

    Short interest in Clene has recently decreased by 1.86%, indicating that investor sentiment is improving.
  • Dividend Yield

    Clene does not currently pay a dividend.

  • Dividend Growth

    Clene does not have a long track record of dividend growth.

  • News Sentiment

    Clene has a news sentiment score of 0.91. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.59 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Clene this week, compared to 4 articles on an average week.
  • Search Interest

    Only 1 people have searched for CLNN on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • MarketBeat Follows

    2 people have added Clene to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Clene insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    28.30% of the stock of Clene is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    23.28% of the stock of Clene is held by institutions.

  • Read more about Clene's insider trading history.
Receive CLNN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Clene and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

CLNN Stock News Headlines

Research Analysts Set Expectations for Clene FY2026 Earnings
My $247 scanner for $7
Bill Poulos is cutting the price of his $247 Instant Scanner to $7 for Black Friday. It's a one-time payment that covers a full year, with no subscription and no re-bills. Every night after the close, the scanner screens nearly a thousand of America's biggest stocks. It returns a short list of qualifying setups with the exact buy price next to each one. There's nothing to install. If you decide it's not for you, you get the $7 back and keep the scanner for the year.tc pixel
Clene (NASDAQ:CLNN) Stock Lifted to Hold by Wall Street Zen
Clene Files NDA for ALS Therapy CNM-Au8
See More Headlines

CLNN Stock Analysis - Frequently Asked Questions

Clene's stock was trading at $5.87 at the start of the year. Since then, CLNN shares have decreased by 37.6% and is now trading at $3.66.

Clene Inc. (NASDAQ:CLNN) announced its earnings results on Wednesday, November, 4th. The company reported $0.05 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.45) by $0.50. The business had revenue of $56 thousand for the quarter, compared to the consensus estimate of $70 thousand.

Clene's stock reverse split on Thursday, July 11th 2024.The 1-20 reverse split was announced on Thursday, July 11th 2024. The number of shares owned by shareholders was adjusted after the market closes on Thursday, July 11th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Clene's top institutional shareholders include State Street Corp (0.26%) and Lunt Capital Management Inc. (0.16%). Insiders that own company stock include General Resonance Llc, David J Matlin, Chidozie Ugwumba and Mark Mortenson.
View institutional ownership trends
.

Shares of CLNN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Clene investors own include NVIDIA (NVDA), Tesla (TSLA), Ford Motor (F), CVS Health (CVS), Enterprise Products Partners (EPD), Block (XYZ) and Energy Transfer (ET).

Company Calendar

Last Earnings
11/04/2026
Today
11/16/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:CLNN
CIK
1822791
Fax
N/A
Employees
79
Year Founded
N/A

Price Target and Rating

High Price Target
$48.00
Low Price Target
$23.00
Potential Upside/Downside
+829.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.71
Research Coverage
7 Analysts

Profitability

EPS (Trailing Twelve Months)
($2.60)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$26.17 million
Net Margins
-11,274.79%
Pretax Margin
-11,271.43%
Return on Equity
N/A
Return on Assets
-77.56%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.85
Quick Ratio
0.84

Sales & Book Value

Annual Sales
$200 thousand
Price / Sales
263.52
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($1.03) per share
Price / Book
-3.55

Miscellaneous

Outstanding Shares
14,400,000
Free Float
10,325,000
Market Cap
$52.70 million
Optionable
Optionable
Beta
1.04
7 Stocks That Could Lead the Next Market Boom Cover

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

This page (NASDAQ:CLNN) was last updated on 11/16/2026 by MarketBeat.com Staff.
From Our Partners